HMOX1

HMOX1 is the gene that encodes the inducible heme oxygenase 1 (HO-1) enzyme in humans. HO-1 catalyzes the first step in heme degradation, converting heme to biliverdin, while releasing iron and carbon monoxide. Biliverdin is rapidly reduced to bilirubin; both biliverdin and bilirubin have antioxidant properties, and carbon monoxide can act as a signaling molecule with anti-inflammatory and vasodilatory effects. The overall activity of HO-1 contributes to cellular protection under stress.

Expression and regulation of HMOX1 are tightly controlled. The enzyme is low under normal conditions but is upregulated in response to oxidative stress, hypoxia, heat shock, heavy metals, and inflammatory stimuli. The regulation involves the Nrf2-ARE pathway, with transcriptional activation promoted by antioxidant response elements and repressed by factors such as Bach1 in the absence of stress. The promoter of HMOX1 contains regulatory motifs, including variable GT dinucleotide repeats, whose length can influence the level of inducibility.

Genetics and distribution: HMOX1 is located on chromosome 22q12 in humans, and HO-1 is expressed across many tissues with levels that vary by cell type and environmental conditions. HO-1 is part of a broader family of heme oxygenases, including the constitutively expressed HO-2.

Clinical significance and research: HO-1 activity generally protects against oxidative injury, inflammation, and ischemia-reperfusion damage in experimental models. Deficiency or inadequate induction can increase susceptibility to stress. Polymorphisms in the HMOX1 promoter, particularly GT-repeat length, have been studied for associations with susceptibility or outcomes in inflammatory, cardiovascular, and other diseases, though findings are context dependent. Therapeutic interest exists in pharmacologic induction of HO-1 to achieve cytoprotection in transplantation, neuroprotection, and vascular injury, balanced against potential effects on iron metabolism.

---